Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?

Regeneron Pharmaceuticals (REGN) - KPIs | Sterling

Period	Clinical programs (printed floor)
Q2 2026	50

Period	Printed result
COURAGE	Trevogrumab + semaglutide: muscle preservation; no extra weight loss

Period	US EYLEA HD ($M)	US EYLEA + HD ($M)	HD share of US franchise (%)
Q2 2026	596.3	1,008.5	60

Period	Net cash ($B)
Q2 2026	15.1

Period	Workstream	Printed status
Q2 2026	China (Hansoh)	Phase 3 underway
Q2 2026	United States	Phase 3 planned 2H 2026
Q2 2026	Olatorepatide + Praluent	Combination program printed

Product	U.S. ($M)	Rest of world ($M)	Total ($M)	YoY change (%)
Dupixent	4,561.1	1,437.1	5,998.2	38
EYLEA HD	596.3	366.3	962.6	52
EYLEA	412.2	300.2	712.4	-52
Total EYLEA HD and EYLEA	1,008.5	666.5	1,675	-21
Libtayo	342.6	146.8	489.4	30
Praluent	74.7	190.9	265.6	20
Kevzara	143.4	62.5	205.9	35
Lynozyfic	16.2	0.3	16.5
Other products	54	30.6	84.6	17

Employees